Abstract
We assessed the impact of a reduced-dose (10 mg × 3/week for 4 weeks) schedule of alemtuzumab in 10 patients with pretreated cutaneous/peripheral T-cell lymphomas. The overall response rate was 60% (2 complete responses and 4 partial responses). In terms of infectious toxicity, cytomegalovirus reactivation occurred in 1 (10%) patient.
Original language | English |
---|---|
Pages (from-to) | 702-703 |
Number of pages | 2 |
Journal | Haematologica |
Volume | 90 |
Issue number | 5 |
Publication status | Published - May 2005 |
Keywords
- Alemtuzumab
- CTCL
- Low-dose
- PTCL
ASJC Scopus subject areas
- Hematology